Skip to content
6-K

Foreign Interim / Material

Freeline Therapeutics Holdings plc

0000950170-23-024629

← back to feed
Filed
May 30, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2023 · Mar 31, 2023 65.76M sh
Shares Diluted Q1 2023 · Mar 31, 2022 42.64M sh
Capex Q1 2023 · Mar 31, 2023 $392K
Capex Q1 2023 · Mar 31, 2022 $526K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$18.44M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$26.58M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $55.42M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $47.28M
Cash And Equivalents Q1 2023 · Mar 31, 2022 $113.1M
Stockholders Equity Q1 2023 · Mar 31, 2023 $55.99M
Stockholders Equity Q1 2023 · Dec 31, 2022 $52.41M
Current Liabilities Q1 2023 · Mar 31, 2023 $22.74M
Current Liabilities Q1 2023 · Dec 31, 2022 $30.97M
Total Liabilities Q1 2023 · Mar 31, 2023 $25.38M
Total Liabilities Q1 2023 · Dec 31, 2022 $34.23M
Current Assets Q1 2023 · Mar 31, 2023 $63.87M
Current Assets Q1 2023 · Dec 31, 2022 $67.63M
Total Assets Q1 2023 · Mar 31, 2023 $81.37M
Total Assets Q1 2023 · Dec 31, 2022 $86.64M
Eps Diluted Q1 2023 · Mar 31, 2023 $0.02
Eps Diluted Q1 2023 · Mar 31, 2022 −$0.63
Eps Basic Q1 2023 · Mar 31, 2023 $0.02
Eps Basic Q1 2023 · Mar 31, 2022 −$0.63
Sga Expense Q1 2023 · Mar 31, 2023 $8.05M
Sga Expense Q1 2023 · Mar 31, 2022 $8.22M
Rd Expense Q1 2023 · Mar 31, 2023 $10.89M
Rd Expense Q1 2023 · Mar 31, 2022 $19.95M
Net Income Q1 2023 · Mar 31, 2023 $1.17M
Net Income Q1 2023 · Mar 31, 2022 −$26.73M
Operating Income Q1 2023 · Mar 31, 2023 −$20.08M
Operating Income Q1 2023 · Mar 31, 2022 −$28.17M